Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Oct 23.
Published in final edited form as: Mucosal Immunol. 2023 Sep 14;16(5):699–710. doi: 10.1016/j.mucimm.2023.07.004

GL7 ligand expression defines a novel subset of CD4+ TRM cells in lungs recovered from pneumococcus

Carolina Lyon De Ana 1,2, Anukul T Shenoy 1,9, Kimberly A Barker 1,2, Emad I Arafa 1,3, Neelou S Etesami 1,2, Filiz T Korkmaz 1,4, Alicia M Soucy 1, Michael P Breen 1,2, Ian MC Martin 1, Brian R Tilton 1, Priyadharshini Devarajan 4, Nicholas A Crossland 6,7, Riley MF Pihl 1,3,5, Wesley N Goltry 1, Anna C Belkina 1,5,7, Matthew R Jones 1,3, Lee J Quinton 1,2,3,4,7, Joseph P Mizgerd 1,2,3,8,
PMCID: PMC10591822  NIHMSID: NIHMS1937089  PMID: 37604254

Abstract

Streptococcus pneumoniae is the most common etiology of bacterial pneumonia, one of the leading causes of death in children and the elderly worldwide. During non-lethal infections with S. pneumoniae, lymphocytes accumulate in the lungs and protect against reinfection with serotype-mismatched strains. Cluster of differentiation CD4+ resident memory T (TRM) cells are known to be crucial for this protection, but the diversity of lung CD4+ TRM cells has yet to be fully delineated. We aimed to identify unique subsets and their contributions to lung immunity. After recovery from pneumococcal infections, we identified a distinct subset of CD4+ T cells defined by the phenotype CD11ahiCD69+GL7+ in mouse lungs. Phenotypic analyses for markers of lymphocyte memory and residence demonstrated that GL7+ T cells are a subset of CD4+ TRM cells. Functional studies revealed that unlike GL7 TRM subsets that were mostly (RAR-related Orphan Receptor gamma T) RORγT+, GL7+ TRM cells exhibited higher levels of (T-box expressed in T cells) T-bet and Gata-3, corresponding with increased synthesis of interferon-γ, interleukin-13, and interleukin-5, inherent to both T helper 1 (TH1) and TH2 functions. Thus, we propose that these cells provide novel contributions during pneumococcal pneumonia, serving as important determinants of lung immunity.

INTRODUCTION

Lower respiratory infections impart one of the highest global burdens of disease worldwide and are a leading cause of death, especially in children and the elderly13. The most common bacterial source of pneumonia is Streptococcus pneumoniae (Spn). Over 100 different serotypes have been identified based on differences in the Spn capsule4. While effective serotype-specific vaccines have reduced mortality from invasive pneumococcal disease worldwide5,6, infections with non-vaccine serotypes continue to increase7,8. Our group and others have demonstrated that self-limiting experimental pneumonia or immunization leads to an accumulation of resident memory lymphocytes that provide protection across multiple Spn serotypes, termed heterotypic immunity911. Leveraging our knowledge about these resident lymphocytes will be crucial in developing strain-independent Spn vaccines.

Resident memory T cells (TRM) localize to non-lymphoid tissues and deliver local and fast effector functions at the time of reinfection913. Lung TRM cells have been shown to provide crucial long-term protection against many bacterial and viral agents10,1215. TRM cells deliver essential cues to their environment and cooperate with epithelial cells, B cells, and other T cells to choreograph important functions needed for immune protection, such as lymphocyte and neutrophil recruitment1618. TRM cells have been characterized by expression of the surface markers cluster of differentiation CD11a and CD69 at rest10,12, although heterogeneity within this population is gaining recognition18,19. Previous work by our group demonstrates the presence of diverse and novel subsets of CD4+ and CD8+ TRM and B resident memory cells in mouse lungs after pneumococcal exposures20,21, but the extent of lung TRM cell diversity and their roles in immune protection are still unclear.

In this work, we used full-spectrum flow cytometry (FSFC) to study CD4+ T cells in the lungs of Spn-experienced mice. We have identified previously undescribed subsets of CD4+ TRM cells that express the GL7 antibody ligand, known as a marker of germinal center B cells. GL7 is a monoclonal antibody that recognizes surface glycans sialylated with N-Acetylneuraminic Acid (Neu5Ac)22. Throughout this study, we will denote cells expressing the ligand of GL7 (Neu5Ac) as GL7+. Our analyses revealed that this novel subset of GL7+ T cells represents a non-recirculating resident population of CD4+ TRM cells with a unique transcription factor profile that secretes a distinct combination of cytokines. Our study introduces GL7+ TRM cells as a discrete population of lung-resident lymphocytes arising after recovery from pneumococcal pneumonia.

RESULTS

Recovery from pneumonia leads to subpopulations of CD4+ T cells arising in the lungs

CD4+ T cells mediate heterotypic immune protection against pneumococcal pneumonia10,16. Comprehensive phenotyping of Spn-experienced lungs revealed a previously unappreciated heterogeneity of resident lymphocytes20. Following this approach, we combined FSFC using a 22-color immunopheno-typing panel20 to further investigate lung CD4+ TRM cells in Spn-experienced lungs. Adult mice received two intratracheal (i.t.) instillations of Spn serotype 19F (Sp19F) directed to the left lobes (LLs) (Fig. 1A). The two infections result in a self-limiting pneumonia that promotes heterotypic immune remodeling10. After a resting period of 30 days, we collected the lungs and processed them for further studies. We used a panel of 21 surface markers to characterize and distinguish lymphocyte subsets20, concatenated data from six experienced mice, subsetted live extravascular (i.v.CD45.2) CD4+ T cells (Supplementary Fig. 1), and projected the multiparameter data into 2-dimensional space using optimized parameter T-distributed stochastic neighborhood embedding (opt-SNE)23 (Fig. 1B). To identify the cells subsets on the resulting map, we overlaid heatmaps of normalized expression of each marker over the opt-SNE visualization (Fig. 1C, Supplementary Fig. 1B). We observed that three markers, CD11a, CD69, and GL7, could separate CD4+ T cells into distinct populations. Following heatmap expression, we designed a supervised gating strategy to categorize lung CD4+ T cells which confirmed four major subsets: CD11ahiCD69+GL7, CD11ahiCD69+GL7+, CD11ahiCD69GL7 and CD11alo (Figs. 1D and 1E, Supplementary Fig. 2A), referred to henceforth as CD69+GL7, CD69+GL7+, CD69GL7 and CD11alo respectively. All but the CD11alo subsets were CD44hi and CD62Llo, characteristic of memory T cells, while the CD11alo cells were CD44loCD62Lhi, characteristic of naive T cells24,25 (Figs. 1F and 1G). These phenotypes suggest that both CD69+ populations were TRM cells1214, with expression of GL7 ligand differentiating a distinct subset (Figs. 1F and 1G). The GL7-reactive CD4+ cells were observed in loose aggregates within the interstitial connective tissue of bronchovascular bundles after recovery from pneumococcal pneumonia, in association with other CD4+ cells that were not GL7-reactive (Fig. 1H).

Fig. 1.

Fig. 1

Lungs from pneumococcus-experienced mice contain multiple subsets of memory CD4+ T cells. (A) Model of heterotypic immunity. Adult female mice are infected intratracheally into the left lobe (LL) of the lungs with Streptococcus pneumoniae serotype 19F (Sp19F) on day 0 and 7 then rested until day 35, referred to as experienced. Three minutes before LL collection, mice were injected Intravenously. with mouse anti-CD45.2 antibody then processed for flow cytometry. (B) Optimized parameter T-distributed stochastic neighborhood embedding (opt-SNE) visualization depicting live lung (ivCD45.2) CD45+CD3+CD4+ T cells of concatenated data from n = 6 mice gathered over two independent experiments. (C) Heat map depiction of expression level of surface markers overlayed on opt-SNE map. (D) Representative manual gating of flow cytometry data of lung CD4+ T cells, n = 6 mice, two independent experiments. (E) Manual gates overlayed on opt-SNE map.(F) Representative histograms of CD62L and CD44 in lung CD4+ T cells, n = 6, 2 independent experiments. (G) Heatmap of average mean fluorescence intensity (MFI) normalized to fluorescence minus one (FMO) controls or minimal MFI and maximal MFI, n = 6, two independent experiments. Each group was compared to CD11a for statistical comparisons, one-way ANOVA *p < 0.002. (H) Representative immunofluorescent micrograph showing anatomical distribution of CD4+ (yellow) and GL7+6 cells in experienced mouse lungs at 35 dpi, with white arrows indicating some double-positive cells. (I) Fold change of Cmah mRNA in GL7+ over GL7 sorted, unstimulated, lung CD4+CD11a+CD69+ T cells, n = 3, 6 LL pooled per sample, Welch’s T-test, *p value = 0.0210.

GL7 detects surface glycans sialylated with Neu5Ac22,26. In resting lymphocytes, the enzyme cytidine monophospho-Neu5Ac hydroxylase (CMAH) catalyzes the hydroxylation of Neu5Ac into N-glycolylneuraminic acid (Neu5Gc)26. During lymphocyte activation, Cmah is downregulated, resulting in glycan sialylation with Neu5Ac22,2629. GL7 ligand expression occurs in germinal center B cells (BGC) and GC T follicular helper (TFH) cells, but such phenotype has not been reported in memory T cells28,30. To examine if CD69+GL7+ cells have a reduced level of CMAH, we measured Cmah transcripts in CD69+GL7+ and CD69+GL7 cells sorted from experienced mouse lungs. CD69+-GL7+ cells demonstrated a reduced level of Cmah transcripts, suggesting the expression of GL7 ligand associates with a reduced level of the enzyme and an additional phenotypic difference between TRM cell subsets (Fig. 1I, Supplementary Fig. 2B). Together, these results suggest CD4+ TRM cells in pneumococcal experienced mouse lungs can be separated into subpopulations based on their differential expression of surface markers including the GL7 ligand Neu5Ac.

The GL7+ T cells in recovered lungs are not circulating, proliferating, follicular, or restricted to pneumococcal infections

In agreement with previous reports by our group and others10,11,16,21, we observe that all four subsets of lung T cells, CD11ahiCD69+GL7, CD11ahiCD69+GL7+, CD11ahiCD69GL7 and CD11alo, increased in number after pneumococcal experience (Fig. 2A). The largest fraction of CD4+ T cells in naïve lungs corresponded to CD11alo cells; in experienced lungs, CD11ahi subsets predominated, including the more resident-like CD69+-GL7 (Fig. 2A), supporting immune remodeling after infection. To further understand the dynamics of these subsets after Spn infections, we collected the left lung lobes at eight different timepoints from 0 to 35 days after exposure (Fig. 2B). The second Sp19F infection, designed to facilitate local antigen presentation in the lung, triggered acute accumulation of T cells (Supplementary Fig. 3A). The numbers of cells from all four subsets reached a maximum at 3 days after the second infection (10 dpi) (Fig. 2C). From 24 to 35 dpi both CD69+GL7+ and CD69+GL7 subsets plateau and their cell numbers stabilized, while CD69 and CD11alo cells continuously decreased over these timepoints (Fig. 2C). The proportion of CD4+ T cells that are CD69+GL7+ increased in the lungs after the second infection, and it became progressively greater over successive timepoints (Fig. 2D, Supplementary Fig. 3A).

Fig. 2.

Fig. 2

CD69+GL7+ subsets of CD4+ T cells have distinct dynamic patterns of accumulation in mouse lungs. (A) Numbers of cells (above) and percentage of lung CD4+ T cells in LL (below) of each subset from saline or Spn experienced mice at 35dpi, n = 6, two independent experiments. Bar graphs of mean and error bars of standard error of mean5, 2-way ANOVA with Bonferroni multiple comparisons test, ***p < 0.0003, ****p < 0.0001. (B) Diagram of timeline of lung collection. Sp19F intratracheally. on days 0 and 7. (C) Average number of cells in LL at every collection timepoint, n = 6 per timepoint, 2 independent experiments, error bars are SEM. (D) Average percent of CD4+ T cells in LL from CD69+GL7+ subset, n = 6 per timepoint, two independent experiments, error bars are SEM. One-way ANOVA with Bonferroni multiple comparisons test, ***p = 0.0004 ****p < 0.0001. FTY720 or vehicle Intraperitonealy to experienced mice at 1mg/kg every other day for 12 days. (E) Representative flow cytometry plots of lung CD4+T cells from LL, n = 10 per group, two independent experiments. (F) Quantification of percent of CD4+ T cells in LL, error bars are SEM. Two-way ANOVA with Bonferroni multiple comparisons test, **p = 0.0013 ****p < 0.0001.

TRM cells reside in the lung after infections rather than regularly recirculating through blood and secondary lymphoid organs1015. To evaluate if the CD69+GL7+ and CD69+GL7 subsets were extravasating from the lungs, we treated experienced mice with FTY720 every alternate day for 12 days prior to lung collection (Supplementary Figs. 3B and 3C). FTY720 prevents sphingosine-1-phosphate (S1P)-mediated T cell egress from lymph nodes and has been widely utilized to evaluate T cell migration in multiple tissues3133. We observed the proportion of neither CD69+GL7+ nor CD69+GL7 subsets of CD4+ T cells were affected by FTY720 treatment, while CD11alo subsets were reduced significantly (Figs. 2E and 2F). These data suggest that the GL7+ subset, like other TRM cells3133, are not in constant S1P-mediated circulation but instead, get retained in the lungs long-term.

To determine whether CD69+GL7+ cells that accumulated in Spn-experienced lungs were in a state of proliferation, we measured their expression of Ki6719. Although Ki67+ cycling cells were abundant in the first days after infection, both CD69+GL7+ and CD69+GL7 subsets were equally low in Ki67 expression at the late timepoints (Fig. 3A, Supplementary Fig. 4A). Thus, neither of the two TRM cell subsets were proliferating in the resting lungs. Despite the absence of actively proliferating cells, these GL7+ subsets of memory CD4+ T cells could persist in the lungs for at least 6 months (Figs. 3B and 3C, Supplementary Fig. 5B). Together, these data suggest CD69+GL7+ T cells in the Spn-experienced lung have resident memory-like characteristics resembling TRM cells19. Hereafter, CD69+GL7+ and CD69+GL7-subsets from these lungs will be referred to as GL7+ and GL7 TRM cells.

Fig. 3.

Fig. 3

CD69+GL7+ subsets of CD4+ T cells have characteristics of resident memory T cells. (A) Flow cytometry of single cell suspensions from LL collected at 10, 14 and 35dpi. Representative plots of Ki67 staining in GL7+ or GL7 of CD69+CD11a+ CD4+ T cells in LL. Mean +/− standard deviation of percent of parent, n = 5 to 6 per dpi, two independent experiments. LL of Sp19F experienced mice collected at 6, 18 and 24 wpi. (B) Representative flow cytometry plots of GL7 staining, n = 4 to 6 per group, two independent experiments. (C) Quantification of percent of GL7+ o of CD69+CD11a+ CD4+ T cells in LL, error bars are SEM, ordinary one-way ANOVA with Tukey multiple comparisons test. Mice infected intratracheally to the LL with SP19F, killed Klebsiella pneumoniae or Influenza A/PR8 on day 0 and 7 and rested until day 40. LL collected for flow cytometry. (D) Representative flow cytometry plots of GL7 staining, n = 6 per group, two independent experiments. (E) , Quantification of percent of TRM cells of CD4+ T cells (right) and percent of GL7+ in CD4+ TRM cells in LL of each infection model, error bars are SEM, ordinary one-way ANOVA with Tukey multiple comparisons test, *p = 0.0464, ****p < 0.0001. LL from Sp19 experienced mice processed with manual digestion method after anti-ARTC2 nanobody Intravenous injection for 30min. (F) Quantification of percent of TRH and TRM cells of parent (CD44+CD4+ T cells), error bars are SEM, paired T-test, ****p < 0.0001. (G) Representative flow cytometry plots of of TRH and TRM cells (right) and GL7 staining (left) of parent population, n = 6, two independent experiments. (H) Quantification of percent of GL7+ percent of parent (TRM or TRH), error bars are SEM, paired T-test, **p = 0.0015.

GL7 ligand can be expressed on TFH cells in germinal centers28,30. A subset of lung-resident cells with TFH-like biology, T resident helper7 cells, arises in the lungs of mice recovered from influenza infection17,18. Influenza infections as well as Klebsiella pneumoniae preparations elicit tertiary lymphoid structures in the lungs3436, which are not observed after recovery from pneumococcus10,11. Although the numbers of CD4+ TRM cells varied across microbial challenges, CD69+GL7+ memory CD4+ cells were identified in all settings and at similar proportions (Figs. 4C and 4D). To evaluate if the GL7+ TRM cells in lungs recovered from pneumococcus resemble TRH cells that have been described after influenza, we evaluated the expression of TRH-associated markers17,18. Using a mechanical digestion method reported to conserve TRH cell recovery from the lungs17,18, we observed very few PSGL1lowFR4high TRH cells (Fig. 3G, Supplementary Fig. 5A). GL7 + cells were found among the PSGL1high-FR4low TRM cells, not the PSGL1lowFR4high TRH cells (Figs. 3H and 3J, Supplementary Fig. 5A). Furthermore, BCL6+ and CXCR5+ cells were rare among the memory CD4+ T cells in lungs from mice recovered from pneumococcus, and when found these cells tended to be GL7 (Supplementary Fig. 5B). We conclude that GL7+ TRM cells are distinct from follicular-like lung TRH cells.

Fig. 4.

Fig. 4

GL7+ TRM cells secrete similar cytokines reflective of their transcription factor profiles. Intracellular cytokine staining (ICS) of lung (Intravenous injection CD45.2) CD4+TRM cells stimulated ex vivo with PMA/Ionomycin in presence of golgi plug and golgi block. (A) Representative plot of IL-17A (right) and quantification of frequency of IL-17A+ cells (left) in parent population (GL7+ or GL7 CD4+TRM cells). (B) Representative plot of IFN-γ (right) and quantification of frequency of IFN-γ+ cells (left) in parent population (GL7+ or GL7 CD4+TRMcells). (C) Representative plots of IL-5/IL-13 (right) and quantification of percent of IL-13+ and/or IL-5+ cells in parent population (GL7+ or GL7 CD4+TRM cells). Paired t test, ***p = 0.0002, ****p < 0.0001. n = 13, two independent experiments.

Cytokine expression by GL7+ TRM subsets reveals functional diversity

A cardinal function of TRM cells in mucosal tissues is cytokine secretion10,12,14,15,37. Our group and others have shown that cytokines secreted by lung CD4+ TRM cells provide important signals to neighboring cells to orchestrate immune protection1618,21. To determine if GL7 expression highlighted a functionally distinct subset of lung CD4+ T cells, we designed an FSFC panel that included four cytokines and major TRM lineage markers. We combined intracellular cytokine staining (ICS) with preliminary antibody labeling to track GL7 and CD69 surface marker expression throughout ex vivo stimuli with PMA/Ionomycin. As expected, the majority of lung CD4+ T cells from Spn-recovered lungs expressed IL-17A upon stimulation, and this applied to both the GL7+ and GL7 subsets (Fig. 4A, Supplementary Fig. 6A). However, the distribution of cytokine-secreting cells differed between the T cell subsets. Compared to GL7 TRM cells from the same lung, the GL7+ TRM cells were less frequently IL-17A-producers, and more frequently IFN-γ or IL-5 and/or IL-13 producers (Figs. 4A4C). This insinuates a potential functional difference in this subset of T cells, less TH17-like and more prone to TH1 and TH2-like responses. These data suggest GL7+ TRM cells have a functional difference that results in a reduced output of IL-17A and an increase in IFN-γ, IL-5, and/or IL-13 after stimulation.

GL7+ TRM subsets have distinct transcription factor profiles

Cytokine expression from helper T cells is typically dependent on cellular phenotypes dictated by lineage-defining transcription factors (LDTF)38. We used a flow cytometry panel with T-bet, Gata-3, RORγT, and FoxP3, to help us discriminate the TH1, TH2, and TH17 helper and Treg subsets of T cells, respectively21,38. Within the GL7+ TRM subset, there was a lower frequency of RORγT+ and more Gata-3+ cells in comparison to the GL7 counterparts (Figs. 5A and 5B, Supplementary Fig. 7A). FOXP3+ cells were rare among both GL7+ and GL7 TRM cells, but a little less so in the former (Supplementary Fig. 7B) This implies that the GL7+ T cells may be more predisposed to the TH2-like lineage and less predisposed to the TH17-like lineage compared to the GL7 cells from the same lungs, consistent with the cytokine expression data.

Fig. 5.

Fig. 5

GL7+ TRM cells have unique transcription factor profiles. (A) Representative flow cytometry plots of intracellular lineage-defining transcription factor (LDTF) staining in live lung CD4+TRM cells and (B) Frequency of LDTF+ cells in parent population (GL7+ and GL7 CD4+TRM). Paired t test, **p = 0.005. (C) Relative multipotency index21 of GL7+ and GL7 lung (Intravenous injection CD45.2) CD4+TRM cells. Bar graphs of mean and error bars of SEM. Ratio paired t test, **p = 0.0044. n = 9, two independent experiments. (D) Frequency of GL7+ or GL7 CD4+TRM from each lineage in parent population (GL7+ and GL7 CD4+TRM). Bar graph of mean and error bars of SEM. Two-way ANOVA with Bonferroni multiple comparisons test, ***p = 0.0008

While expression of a single transcription factor has been widely used to define TH cell lineages38, multi-lineage CD4+ T cell plasticity is known21,39,40. Studies by our group recently demonstrated that many TRM cells in Spn-experienced lungs express multiple lineage-defining transcription factors simultaneously20,21. To evaluate if GL7+ TRM cells represented a subset with unique combinations of transcription factors, we combined LDTF data from Fig. 4 with a nested manual gating strategy that measured the expression of one, two, or three of the factors simultaneously in each TRM subset among FOXP3 cells (Supplementary Fig. 7C)21. While cytokine analyses suggested that multifunctionality was rare (Supplementary Fig. 6B), lung T cells often exhibited multiple lineage-defining transcription factors (Fig. 5D) and the relative multipotency index21 revealed that the GL7+ TRM cells tend to express fewer compared to the GL7 counterparts (Fig. 5C). Examining the co-expression phenotypes more specifically, we identified eight subpopulations, each of which was present in both TRM subsets. The most common phenotype was Gata-3+RORγT+ cells, which may reflect a skewing toward Th2/Th17 (Fig. 5D). Within GL7 TRM cells, the second most common subtype was a triple-negative population that did not express any of the lineage-defining transcription factors included in our study. In GL7+ TRM cells, the second most common subtype was Gata-3+ cells lacking the other transcription factors, which were significantly less abundant within the GL7 population (Fig. 5D, Supplementary Fig. 6B).

These data further support the concept that GL7+ cells represent a distinct subphenotype of lung TRM cells. While subsets exist among both GL7+ and GL7 TRM cells, the differences in distribution suggest the former tilt away from TH17 and toward TH2 compared to the latter, consistent across transcription factor content and cytokine expression.

Upon further evaluation, we observed different levels of expression of GL7 within GL7+ TRM cells, which we defined as GL7hi and GL7lo. Inspection of the GL7 vs. transcription factor data suggested that cells with lower or higher amounts of GL7 (Fig. 6A) may have different expression levels of LDTFs. The GL7lo subsets had frequencies of RORγT+ cells and T-bet+ cells that matched GL7 TRM cells, but Gata-3+ cells were enriched in GL7lo T cells (Fig. 6BC). In contrast, the GL7hi subsets had decreased frequencies of RORγT+ cells and increased frequencies of T-bet+ cells compared to the GL7 counterparts, while Gata-3+ cells were unchanged (Fig. 6BC). Altogether, these transcription factor results match the cytokine expression data well, providing consistent evidence for decreased TH17 but increased TH1 and TH2 skewing in the GL7+ lung CD4+ TRM cells compared to the GL7 lung CD4+ TRM cells.

Fig. 6.

Fig. 6

GL7+ TRM cells are a bimodal population with different roles. (A) Manual gating of GL7, GL7Low and GL7High in lung (Intravenous injection CD45.2) CD4+TRM cells. (B) Representative flow cytometry plots of intracellular LDTF staining in lung (Intravenous injection CD45.2) CD4+TRM with GL7, GL7Low and GL7High gates. (C) Frequency of RORγT+, T-bet+ and Gata-3+ cells in parent population (GL7, GL7Low and GL7HighCD4+TRM). Bar graphs of mean and error bars of SEM. One-way ANOVA with Tukey test of multiple comparisons. *p = 0.02, **p = 0.003, ****p < 0.0001. n = 9, two independent experiments.

DISCUSSION

Our study highlights a novel population of resting CD4+ T cells residing in lungs that have recovered from pneumonia, distinguished by expression of Neu5Ac that is recognized by the GL7 monoclonal antibody. These cells share many characteristics with GL7 T cells from these lungs, including a stable and long-lived CD11aHiCD69+CD62LLoCD44HiKi67 phenotype, which led us to conclude they are lung-resident memory lymphocytes, further supported by FTY720 studies. However, the GL7+ T cells in these lungs differ from their GL7 neighbors. The former expresses lower levels of the CMAH enzyme contain a different balance of LDTFs at rest and produce a different mixture of cytokines when activated. We propose that GL7 marks a previously unrecognized subset of lung TRM cells.

GL7 reactivity is not unprecedented for mouse lymphocytes. GL7 ligand expression has been detailed in cells from mice in primary and secondary lymphoid organs, including BGC cells22,26,27,41 as well as a subset of TFH cells whose surface markers include CD4+CXCR5HiGL7+28,30. While CXCR5+ and BCL6+ memory CD4+ T cells could be recovered from Spn-experienced lungs using manual digestion methods, they were mostly GL7. The GL7+ subsets also did not express markers associated with the TFH-like lung TRH cells17,18, suggesting that these GL7+ TRM may not be the TFH phenotype or the newly reported and related TRH cells17,18. GL7 ligand expression is acutely upregulated on B cells and T cells due to in vitro stimulation22,26,27,29. The GL7+ phenotype in these activated naïve cells is due to a transient decrease in CMAH, the reduction of which results in the surface glycan sialylation with Neu5Ac27,29.

We demonstrate that GL7+ TRM cells have low CMAH-like activated naïve cells but with several important distinctions: 1) they are found in resting lungs that have recovered from bacterial or viral pneumonia, but without any ongoing infection or inflammation; 2) they exhibit markers of resident memory cells, 3) they form a stable population that persists long-term; 4) they do not circulate out of the lungs; 5) and they are not proliferating. We believe this may be the first evidence for GL7 ligand expression on resting or memory T cells.

We postulate that GL7+ cells are a distinct subset of lung CD4 + TRM cells that may influence the immune tone of lungs responding to a heterotypic respiratory infection. Most memory TRM cells after a Spn lung infection are of the TH17 lineage that predominantly secretes IL-17A during activation or subsequent reinfection10,21. Previous work from our group and others revealed TRM cells that expressed transcription factors from multiple lineages and could secrete diverse cytokines after ex vivo stimulation20,35,42. Our current work supports these claims and shows such plasticity applies to both GL7 and GL7+ subsets of TRM cells. However, the GL7+ subset appears to favor TH1 and TH2 phenotypes more and the TH17 phenotype less, in comparison to the more numerous GL7 lung TRM cells. This conclusion is based on balances of both the transcription factors and the cytokines in these cells; and suggests TRM cells in Spn-recovered lungs share many similarities, but the GL7+ subset is more poised to provide TH1 and TH2 responses than are GL7 TRM cells, which more robustly favor TH17 responses.

There is still much to learn about these CD4+ TRM cell subsets, but these first results suggest a possible model related to T cell contributions to immune resistance and tissue resilience in acutely infected lungs that have a relevant heterotypic infection history3,43. TH17 responses are key to many aspects of immune resistance against extracellular microbes like pneumococcus34,44; TH1 responses foster antimicrobial activity against intracellular organisms, and also instruct the local immune remodeling of phagocytes and possibly other lung cells45; TH2 responses promote tissue repair and regeneration after injury42,46. Thus, it is possible that the more numerous GL7 TRM cells are most critical to the immune resistance and the elimination of pneumococcus from acutely infected lungs10,16, whereas the scarcer GL7+ TRM cells affect immunomodulation and repair during the tissue recovery stage after pneumonia.

Humans have an inactive CMAH gene and lack a functional CMAH enzyme, therefore surface glycans on human lymphocytes are uniformly sialylated with Neu5Ac47,48. Human lung TRM cells therefore should not exhibit the surface sialylation variations seen here in mouse lung TRM cells. However, humans use a different pathway that functions analogously to sialylation in mice. Humans differentially sulfate lymphocyte surface glycans, and the sulfation state toggles CD22 activation in human cells like glycan sialylation toggles CD22 in mouse lymphocytes4750. CD22 interaction with Neu5Gc or sulfated Neu5Ac inhibits B cells49. A separation of TRM cells by CD22 ligand expression may create subsets of cells that distinctly interact with and regulate CD22+ B cells, advancing another potential biological significance for these lung CD4+ TRM cell subsets. The present results raise new questions about whether human lungs contain two CD4+ TRM cell subpopulations which differ in Neu5Ac sulfation.

As the roles of CD4+ TRM cells in lung immunity continue to be elucidated, we begin to understand that TRM cells are a diverse community with myriad functions that contribute to lung protection. We propose GL7+ TRM cells as one such subset, whose functions may involve differential cytokine secretion, contributing to the overall immune roles of lung TRM cells. Future efforts to develop mucosal vaccines that trigger a robust immune environment in the lungs should consider how the diverse subsets of resident lymphocytes provide mechanisms of protection that result in more effective elimination of microbes and better protection of tissues against damage.

METHODS

Mice

We obtained 6-week-old C57BL/6J51 000664 mice from The Jackson Laboratory (Bar Harbor, ME, USA). All mice were housed in specific pathogen-free conditions with a 12-hour light-dark cycle, and ad libitum access to standard chow and water. Then, 7–8-week-old mice that were adequately rested for 1 week after transfer were used for experiments. Mice were euthanized using isoflurane overdose and death was confirmed using pneumothorax before organ collections. Animal procedures were approved by Institutional Animal Care and Use Committee of Boston University (IACUC).

Streptococcus pneumoniae infections

Spn-specific lung-resident adaptive immunity was generated as previously described10,12,13,15,37. Mice were anesthetized with intraperitoneal (i.p.) administration of ketamine (50mg/kg) and xylazine (5mg/kg) before infection. After surgical exposure of the trachea, sterile saline, or Spn was administered intratracheally via a 24-gauge angiocatheter directed to the LL. Mice received 50μL saline containing 1–5 × 106 CFU of serotype 19F Spn (Strain EF3030) or saline. Seven days later, mice were exposed again to either saline or Sp19F and then allowed to recover for 28–35 days.

Influenza A infection

Mice were anesthetized with i.p. administration of ketamine (50mg/kg) and xylazine (5mg/kg) before infection. After surgical exposure of the trachea, Influenza A/PR8/34 (IAV) was administered intratracheally via a 24-gauge angiocatheter directed to the LL. Mice received 50μL saline containing ~15 plaque-forming units per mouse and allowed to recover for 40 days.

Heat-killed Klebsiella pneumoniae exposure

Klebsiella pneumoniae (KPN) ATCC strain 43816, serotype 2, was prepared as previously described35. It was expanded overnight at 37°C, 5% CO2 in blood agar plates, and replated for 4 hours to reach log phase. Bacteria were diluted to 0.3 optical density measured at 600 nM, pelleted, and washed twice in sterile phosphate buffered saline (PBS) before resuspension in same. Bacteria were heat-killed by incubating at 70°C for 2 hours, and cultures confirmed no remaining bacterial viability. Mice were anesthetized with i.p. administration of ketamine (50mg/kg) and xylazine (5mg/kg). After surgical exposure of the trachea, heat-killed KPN was administered intratracheally via a 24-gauge angiocatheter directed to the LL. Mice received 50 uL containing 2.8 × 106 CFU-equivalents of heat-killed KPN. Seven days later, mice were re-exposed via similar heat-killed KPN administration, and then allowed to recover for 40 days.

Enzymatic digestion of mouse lungs for flow cytometry

To allow enumeration of extravascular (tissue) versus intravascular (circulating) fraction of lymphocytes, mice were anesthetized with i.p. administration of ketamine (50mg/kg) and xylazine (5mg/kg). Three minutes prior to euthanasia, 2 μg fluorochrome-labeled anti-CD45.2 antibody in 100 μL saline were retro-orbitally administered. Right and left lobes of lungs were collected separately in RPMI 1640 with 10% FBS before processing for flow cytometry. Lungs were digested in type 2 collagenase (Worthington Biochemicals, Lakewood, NJ, USA), DNase I (Sigma-Aldrich, St. Louis, MO, USA) and 2.5 mM CaCl2 in PBS for 1 hour at 250–300 rpm at 37°C. Digested lungs were filtered through a 70 μm cell strainer, followed by RBC lysis (Sigma-Aldrich, St. Louis, MO, USA). Cells were blocked with TruStain αCD16/CD32 Fc-Block (BioLegend, San Diego, CA, USA) before staining with optimized dilutions of antibodies (Supplementary Table 1) in 100 uL of FACS buffer and Brilliant Violet Buffer (BD Biosciences, Franklin Lakes, NJ, USA). Conventional flow cytometry was performed on LSR II Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA). High-dimensional full-spectrum flow cytometry was performed on Cytek Aurora (Cytek). SpectraFlo (Cytek) software was utilized for spectral unmixing of the raw full-spectrum data and unmixed data were analyzed with FlowJo software v10.7 (BD Biosciences, Franklin Lakes, NJ, USA). Gating strategies are provided in the Supplemental figures and were based on use of Fluorescence minus one (FMO) controls. For spectral unmixing and conventional compensation, UltraComp compensation beads (Thermo Fisher, Waltham, MA, USA) were used for all fluorochromes except when indicated. Total cell numbers were measured by multiplying the percentage fraction of specified leukocyte subset (in percentage of total) with the total number of cells recovered from each mouse lung.

Manual digestion of mouse lungs for flow cytometry

Experienced mice were anesthetized with i.p. administration of ketamine (50 mg/kg) and xylazine (5 mg/kg). Thirty minutes prior to euthanasia, 2.5 μg of Treg-protector anti-ARTC2 Nanobody (Biolegend, San Diego, CA, USA) was retro-orbitally administered administered. Then, 3–5 minutes prior to euthanasia, 2 μg fluorochrome-labeled anti-CD45.2 antibody in 100 μL saline were retro-orbitally administered. Right and left lobes of lungs were collected separately in cold PBS and manually filtered through a 70 μm cell strainer followed by RBC lysis with Ammonium-Chloride-Potassium (ACK) lysis buffer (Thermo Fisher, Waltham, MA, USA). Cells were blocked with TruStain αCD16/CD32 Fc-Block (BioLegend, San Diego, CA, USA) before staining with optimized dilutions of antibodies (Supplementary Table 1) in 100 uL of FACS buffer and Brilliant Violet Buffer (BD Biosciences, Franklin Lakes, NJ, USA).

Heterotypic immune timeline infection

Adult mice were anesthetized via i.p injection of ketamine and xylazine before infection. Spn suspended in sterile saline was instilled via a 24-gauge angiocatheter directed to the left lobe after surgical exposure of the trachea. Mice were infected i.t. with 50 μL saline containing 1–5 × 106 CFU of serotype 19F Spn (Strain EF3030) or saline. Seven days later, only some mice were exposed again to Sp19F. Control mice received sterile saline on days 0 and 7. Lungs were collected and evaluated on day 0, 1, 3, 10, 14, 24 and 35 and processed for high-dimensional FSFC as previously described20,21. Data were analyzed using FlowJo v10.7 (BD Biosciences, Franklin Lakes, NJ, USA).

FTY720 Dosage

Experienced mice received 1mg/kg of FTY720 (Sigma-Aldrich, St. Louis, MO, USA) i.p. every other day for 12 days. Lungs were collected and processed for flow cytometry staining. Flow cytometry was performed on BD LSR II Flow Cytometer (BD Biosciences, Franklin Lakes, NJ, USA).

Intracellular staining for transcription factors

To evaluate transcription factor and nuclear factors, eBioscience Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher, Waltham, MA, USA) was used following manufacturer’s protocols.

Ex vivo Stimulation and Intracellular cytokine staining

2×106 cells per 1 × 106 cells were blocked with TruStain αCD16/CD32 Fc-Block (Biolegend, San Diego, CA, USA) for 5 minutes before staining with optimized dilutions of mouse anti-CD69 (PE) and GL7 (APC) in FACS buffer for 35 min on ice. Cells were then washed and resuspended and plated in T cell media with 250 ng/mL of Phorbol Myristate Acetate (PMA) (LC Laboratories, Woburn, MA, USA), 1.5 ug/mL Ionomycin (Sigma-Aldrich, St. Louis, MO, USA), and Monensin (Biolegend, San Diego, CA, USA), and Brefeldin A (Biolegend, San Diego, CA, USA) for 6 hours at 37°C and 5% CO2. Cells were then processed for ICS with Intracellular Fixation & Permeabilization Buffer Set (Thermo Fisher, Waltham, MA, USA) following manufacturer’s instructions.

Flow cytometric assisted sorting (FACS)

Single-cell suspensions prepared from digested lungs were prepared with RBC lysis (Sigma-Aldrich, St. Louis, MO, USA) and blocked with TruStain αCD16/CD32 Fc-Block (BioLegend, San Diego, CA, USA) for 5 minutes. Cells were stained in FACS buffer with optimized dilutions of antibodies. GL7+ and GL7 subsets of lung (i.v.CD45.2) CD4+ TRM cells were sorted into 20% FBS RPMI 1640 on ice with FACS-Aria II SORP (BD Biosciences, Franklin Lakes, NJ, USA). After sorting, cells were cultured for 6 hours with T cell media with or without PMA/Ionomycin stimulation at 37°C and 5% CO2. Immediately after, cells were washed and pelleted into (RNA) ribonucleic acid Lysis Buffer (Qiagen, Germantown, MD, USA) and stored at −80°C until RNA extraction.

RNA Extraction and Quantitative Real-time PCR

RNA from sorted T cells was extracted using the RNAeasy Micro Kit (Qiagen, Germantown, MD, USA) following manufacturer’s protocols and stored at −80°C. qRT-PCR was performed using the RNA-to-Ct kit (Thermo Fisher, Waltham, MA, USA). Primers for Cmah were commercially available TaqMan gene expression assays (Mm00483341_m1). We used 18s rRNA (Thermo Fisher, Waltham, MA, USA) to normalize expression levels of mRNA. Fold change of mRNA was calculated from all samples over unstimulated GL7 samples.

Duplex immunohistochemistry (IHC)

Mouse lung samples were embedded in optimal cutting temperature compound and subsequently sectioned at 5 μm using a CM3050 S cryostat (Leica, Wetzlar, Germany), with samples transferred to positively charged slides. Slides were allowed to air dry for 1 hour, before a 15-minute incubation in 10% neutral buffered formalin before progression to immunostaining. IHC was conducted using a Ventana Discovery Ultra (Roche, Basel, Switzerland), with detailed assay parameters outlined in Supplementary Table 2. Secondary (HRP) horse radish peroxidase conjugated species-specific antibodies were utilized to develop primary antibodies (Vector Laboratories, Burlingame, CA), with signal detection through TSA conjugated Opal fluorophores (Akoya Biosciences, Marlborough, MA, USA). Spectral (DAPI) 4′,6-diamidino-2-phenylindole was utilized to label nuclei (Akoya Biosciences, Marlborough, MA, USA). For figure preparation, 200x total magnification digitalized whole slide images of the duplex IHC assay were generated using a multispectral Vectra Polaris Automated Quantitative Pathology Image System (Akoya Biosciences, Marlborough, MA, USA).

T cell Media

T cell media was prepared with RPMI 1640 (Thermo Fisher, Waltham, MA, USA) supplemented with 10% heat-inactivated fetal bovine serum, Penicillin/Streptomycin (100 U/mL, Thermo Fisher, Waltham, MA, USA), 1X Non-essential amino acids (Thermo Fisher, Waltham, MA, USA), 2 mM L-Glutamine (Glutamax, Thermo Fisher, Waltham, MA, USA), 1 nM Na-pyruvate (Thermo Fisher, Waltham, MA, USA), 10 mM HEPES (Thermo Fisher, Waltham, MA, USA) and 0.2 uM b-mercaptoethanol.

Calculation of relative multipotency index

We calculated the Relative Multipotency Index as previously described21, using the following formula:

RelativeMultipotencyIndex=In(%ofmemoryCD4+Tcellsexpressing2LDTFs%ofmemoryCD4+Tcellsexpressing1LDTF)

Statistical analyses

Statistical analyses were performed using Prism Version 9.2.0 (GraphPad, Boston, MA, USA). Differences were deemed statistically significant if the p value was ≤0.05. Each figure legend communicates the number of mice used, the experiment replicates performed, and the statistical tests used to make comparisons. For all figures, data are represented as mean ± (SEM) standard error of the mean.

Supplementary Material

1

FUNDING

This work was supported by NIH grants including K99 HL157555 to ATS, F31 HL142199 to KAB, F31 HL147397 to EIA, F30 HL158109 to NSE, F32 HL147461 to FTK, S10-OD026983 and SS10-OD030269 to NAC, RO1 HL136725 to MRJ, RO1 GM120060 and RO1 HL111449 to LJQ, RO1 AI115053, R35 HL135756, and R33 HL137081 to JPM and T32 HL007035 for support of trainees.

ACKNOWLEDGMENTS

The authors thank Boston University School of Medicine Flow Cytometry Core Facility (BU-FCCF) for their support of this project. We thank all the consenting donors for their generosity. We acknowledge the technical contributions of Aoife K. O’Connell and Hans P. Gertje in their histologic services provided through the NEIDL Comparative Pathology Laboratory (NCPL).

Footnotes

DECLARATION OF COMPETING INTERESTS

The authors have no competing interests to declare.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.mucimm.2023.07.004.

DATA AVAILABILITY

Data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

  • 1.Torres A et al. Pneumonia. Nat. Rev. Dis. Primers 7, 25 (2021). [DOI] [PubMed] [Google Scholar]
  • 2.Mizgerd JP Respiratory infection and the impact of pulmonary immunity on lung health and disease. Am. J. Respir. Crit. Care Med 186, 824–829 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Quinton LJ & Mizgerd JP Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling. Annu. Rev. Physiol 77, 407–430 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Shenoy AT & Orihuela CJ Anatomical site-specific contributions of pneumococcal virulence determinants. Pneumonia (Nathan) 8, 7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Vardanjani HM, Borna H & Ahmadi A Effectiveness of pneumococcal conjugate vaccination against invasive pneumococcal disease among children with and those without HIV infection: a systematic review and meta-analysis. BMC Infect. Dis 19, 685 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wahl B et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob. Health 6, e744–e757 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Hanquet G et al. Serotype replacement after introduction of 10-valent and 13-valent Pneumococcal conjugate vaccines in 10 countries, Europe. Emerg. Infect. Dis 28, 137–138 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Weinberger DM, Malley R & Lipsitch M Serotype replacement in disease after pneumococcal vaccination. Lancet 378, 1962–1973 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Malley R & Anderson PW Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity. Proc. Natl. Acad. Sci. U. S. A 109, 3623–3627 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Smith NM et al. Regionally compartmentalized resident memory T cells mediate naturally acquired protection against pneumococcal pneumonia. Mucosal Immunol. 11, 220–235 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Barker KA et al. Lung-resident memory B cells protect against bacterial pneumonia. J. Clin. Invest 131, e141810 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Turner DL et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7, 501–510 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Masopust D & Soerens AG Tissue-resident T cells and other resident leukocytes. Annu. Rev. Immunol 37, 521–546 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Teijaro JR et al. Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J. Immunol 187, 5510–5514 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.McMaster SR, Wilson JJ, Wang H & Kohlmeier JE Airway-resident memory CD8 T cells provide antigen-specific protection against respiratory virus challenge through rapid IFN-γ production. J. Immunol 195, 203–209 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shenoy AT et al. Lung CD4+ resident memory T cells remodel epithelial responses to accelerate neutrophil recruitment during pneumonia. Mucosal Immunol. 13, 334–343 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Son YM et al. Tissue-resident CD4+ T helper cells assist the development of protective respiratory B and CD8+ T cell memory responses. Sci. Immunol 6, eabb6852 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Swarnalekha N et al. T resident helper cells promote humoral responses in the lung. Sci. Immunol 6:eabb6808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kumar BV et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921–2934 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Shenoy AT et al. CPHEN-011: Comprehensive phenotyping of murine lung resident lymphocytes after recovery from pneumococcal pneumonia. Cytometry A 101, 892–902 (2022). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shenoy AT et al. Antigen presentation by lung epithelial cells directs CD4+ TRM cell function and regulates barrier immunity. Nat. Commun 12, 5834 (2021). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Naito Y et al. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol. Cell Biol 27, 3008–3022 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Belkina AC et al. Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets. Nat. Commun 10, 5415 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sallusto F, Lenig D, Förster R, Lipp M & Lanzavecchia A Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708–712 (1999). [DOI] [PubMed] [Google Scholar]
  • 25.Seder RA & Ahmed R Similarities and differences in CD4+ and CD8+ effector and memory T cell generation. Nat. Immunol 4, 835–842 (2003). [DOI] [PubMed] [Google Scholar]
  • 26.Laszlo G, Hathcock KS, Dickler HB & Hodes RJ Characterization of a novel cell-surface molecule expressed on subpopulations of activated T and B cells. J. Immunol 150, 5252–5262 (1993). [PubMed] [Google Scholar]
  • 27.Naito-Matsui Y et al. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. J. Biol. Chem 289, 1564–1579 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Chen M et al. The development and function of follicular helper T cells in immune responses. Cell. Mol. Immunol 9, 375–379 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Redelinghuys P et al. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J. Biol. Chem 286, 34522–34532 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kerfoot SM et al. Germinal center B cell and T follicular helper cell development initiates in the interfollicular zone. Immunity 34, 947–960 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Cyster JG & Schwab SR Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu. Rev. Immunol 30, 69–94 (2012). [DOI] [PubMed] [Google Scholar]
  • 32.Matloubian M et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355–360 (2004). [DOI] [PubMed] [Google Scholar]
  • 33.Wilk MM et al. Lung CD4 tissue-resident memory T cells mediate adaptive immunity induced by previous infection of mice with Bordetella pertussis. J. Immunol 199, 233–243 (2017). [DOI] [PubMed] [Google Scholar]
  • 34.Lu YJ et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4:e1000159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Amezcua Vesely MC et al. Effector TH17 cells give rise to long-lived TRM cells that are essential for an immediate response against bacterial infection. Cell 178, 1176–1188.e15 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Allie SR et al. The establishment of resident memory B cells in the lung requires local antigen encounter. Nat. Immunol 20, 97–108 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kinnear E et al. Airway T cells protect against RSV infection in the absence of antibody. Mucosal Immunol. 11, 249–256 (2018). [DOI] [PubMed] [Google Scholar]
  • 38.Evans CM & Jenner RG Transcription factor interplay in T helper cell differentiation. Brief. Funct. Genomics 12, 499–511 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Geginat J et al. Plasticity of human CD4 T cell subsets. Front. Immunol 5, 630 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Oestreich KJ & Weinmann AS Master regulators or lineage-specifying? Changing views on CD4+ T cell transcription factors. Nat. Rev. Immunol 12, 799–804 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Murasawa M et al. GL7 defines the cycling stage of pre-B cells in murine bone marrow. Eur. J. Immunol 32, 291–298 (2002). [DOI] [PubMed] [Google Scholar]
  • 42.Harrison OJ et al. Commensal-specific T cell plasticity promotes rapid tissue adaptation to injury. Science 363:eaat6280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Quinton LJ, Walkey AJ & Mizgerd JP Integrative physiology of pneumonia. Physiol. Rev 98, 1417–1464 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Curtis MM & Way SS Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 126, 177–185 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Arafa EI et al. Recruitment and training of alveolar macrophages after pneumococcal pneumonia. JCI Insight 7:e150239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Karo-Atar D et al. A protective role for IL-13 receptor α 1 in bleomycin-induced pulmonary injury and repair. Mucosal Immunol. 9, 240–253 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Macauley MS et al. Unmasking of CD22 co-receptor on germinal center B-cells occurs by alternative mechanisms in mouse and Man. J. Biol. Chem 290, 30066–30077 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Peri S, Kulkarni A, Feyertag F, Berninsone PM & Alvarez-Ponce D Phylogenetic distribution of CMP-Neu5Ac hydroxylase (CMAH), the enzyme synthetizing the proinflammatory human xenoantigen Neu5Gc. Genome Biol. Evol 10, 207–219 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Jellusova J & Nitschke L Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22. Front. Immunol 2, 96 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Nitschke L, Carsetti R, Ocker B, Köhler G & Lamers MC CD22 is a negative regulator of B-cell receptor signalling. Curr. Biol 7, 133–143 (1997). [DOI] [PubMed] [Google Scholar]
  • 51.Garcia S, DiSanto J & Stockinger B Following the development of a CD4 T cell response in vivo: from activation to memory formation. Immunity 11, 163–171 (1999). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

Data Availability Statement

Data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

RESOURCES